Therapeutic Advances in Medical Oncology delivers the highest quality peer-reviewed original research articles, reviews, and scholarly comment on pioneering efforts and innovative studies in the medical treatment of cancer. The journal has a strong clinical and pharmacological focus and is aimed at an international audience of clinicians and researchers in medical oncology, providing an online forum for rapid dissemination of recent research and perspectives in this area.The journal is dedicated to publishing clinical research. We do not publish preclinical research, including basic laboratory research and animal studies.Review articles include expert opinion/perspective reviews (including single-drug and drug class reviews), narrative reviews and therapeutic area reviews. Systematic reviews, meta-analyses, postmarketing and health economic and pharmacoeconomic reviews are also welcomed. The appropriate EQUATOR Network reporting guidelines should be followed (e.g. CONSORT for randomized, controlled trials and PRISMA for systematic reviews/meta-analyses). Therapeutic Advances in Medical Oncology conforms to the ICMJE requirement that clinical trials are registered in a WHO-approved public trials registry at or before the time of first patient enrolment as a condition of consideration for publication. The trial registry name and URL, and registration number must be included at the end of the abstract.The journal adheres to a blind review process in which the reviewer’s name is routinely withheld from the author unless the reviewer requests a preference for their identity to be revealed. Manuscripts are reviewed by at least two referees; and Online First publication is usually within 3 weeks of Acceptance.
《医学肿瘤学治疗进展》是一本开放获取、同行评审期刊，提供最高质量的文章、综述和学术评论，介绍癌症医学治疗方面的开创性努力和创新研究。该杂志以临床和药理学为重点，面向肿瘤医学的临床医生和研究人员，为发表该领域最高质量的文章提供了印刷和在线论坛。该杂志是出版伦理委员会（COPE ）的成员。
HER2-positive breast cancer: new therapeutic frontiers and overcoming resistance
来源期刊：Therapeutic Advances in Medical OncologyDOI：10.1177/1758835919833519
Immunotherapy for hepatocellular carcinoma: recent advances and future perspectives
来源期刊：Therapeutic Advances in Medical OncologyDOI：10.1177/1758835919862692
Clinically relevant drug interactions with multikinase inhibitors: a review
来源期刊：Therapeutic Advances in Medical OncologyDOI：10.1177/1758835918818347
D-methionine alleviates cisplatin-induced mucositis by restoring the gut microbiota structure and improving intestinal inflammation
来源期刊：Therapeutic Advances in Medical OncologyDOI：10.1177/1758835918821021
Real-world comparative effectiveness of nab-paclitaxel plus gemcitabine versus FOLFIRINOX in advanced pancreatic cancer: a systematic review
来源期刊：Therapeutic Advances in Medical OncologyDOI：10.1177/1758835919850367
Current status of hepatocellular carcinoma detection: screening strategies and novel biomarkers
来源期刊：Therapeutic Advances in Medical OncologyDOI：10.1177/1758835919869120
Academic oncology clinicians’ understanding of biosimilars and information needed before prescribing
来源期刊：Therapeutic Advances in Medical OncologyDOI：10.1177/1758835918818335
Pressurized intraperitoneal aerosol chemotherapy with low-dose cisplatin and doxorubicin (PIPAC C/D) in patients with gastric cancer and peritoneal metastasis: a phase II study
来源期刊：Therapeutic Advances in Medical OncologyDOI：10.1177/1758835919846402
Late-line treatment in metastatic gastric cancer: today and tomorrow
来源期刊：Therapeutic Advances in Medical OncologyDOI：10.1177/1758835919867522
Post-neoadjuvant treatment and the management of residual disease in breast cancer: state of the art and perspectives
来源期刊：Therapeutic Advances in Medical OncologyDOI：10.1177/1758835919827714
New frontiers in the medical management of gastrointestinal stromal tumours
来源期刊：Therapeutic Advances in Medical OncologyDOI：10.1177/1758835919841946
Targeting the SLIT/ROBO pathway in tumor progression: molecular mechanisms and therapeutic perspectives
来源期刊：Therapeutic Advances in Medical OncologyDOI：10.1177/1758835919855238
Karonudib is a promising anticancer therapy in hepatocellular carcinoma
来源期刊：Therapeutic Advances in Medical OncologyDOI：10.1177/1758835919866960
SOX11: friend or foe in tumor prevention and carcinogenesis?
来源期刊：Therapeutic Advances in Medical OncologyDOI：10.1177/1758835919853449
Identification of CSPG4 as a promising target for translational combinatorial approaches in osteosarcoma
来源期刊：Therapeutic Advances in Medical OncologyDOI：10.1177/1758835919855491
Opportunities for cannabis in supportive care in cancer
来源期刊：Therapeutic Advances in Medical OncologyDOI：10.1177/1758835919866362
Results from a meta-analysis of immune checkpoint inhibitors in first-line renal cancer patients: does PD-L1 matter?
来源期刊：Therapeutic Advances in Medical OncologyDOI：10.1177/1758835919861905
Novel therapeutic avenues in triple-negative breast cancer: PI3K/AKT inhibition, androgen receptor blockade, and beyond
来源期刊：Therapeutic Advances in Medical OncologyDOI：10.1177/1758835919880429
Neoadjuvant therapy of locally/regionally advanced melanoma
来源期刊：Therapeutic Advances in Medical OncologyDOI：10.1177/1758835919866959
The endonuclease APE1 processes miR-92b formation, thereby regulating expression of the tumor suppressor LDLR in cervical cancer cells
来源期刊：Therapeutic Advances in Medical OncologyDOI：10.1177/1758835919855859
Cotargeting Plk1 and androgen receptor enhances the therapeutic sensitivity of paclitaxel-resistant prostate cancer
来源期刊：Therapeutic Advances in Medical OncologyDOI：10.1177/1758835919846375
Gelsolin-like actin-capping protein has prognostic value and promotes tumorigenesis and epithelial-mesenchymal transition via the Hippo signaling pathway in human bladder cancer
来源期刊：Therapeutic Advances in Medical OncologyDOI：10.1177/1758835919841235
Detection of RAS mutations in circulating tumor DNA: a new weapon in an old war against colorectal cancer. A systematic review of literature and meta-analysis
来源期刊：Therapeutic Advances in Medical OncologyDOI：10.1177/1758835919874653
From guidelines to clinical practice: a roadmap for oncologists for nutrition therapy for cancer patients
来源期刊：Therapeutic Advances in Medical OncologyDOI：10.1177/1758835919880084
The mechanisms of acute interstitial nephritis in the era of immune checkpoint inhibitors in melanoma
来源期刊：Therapeutic Advances in Medical OncologyDOI：10.1177/1758835919875549
The p53/miR-193a/EGFR feedback loop function as a driving force for non-small cell lung carcinoma tumorigenesis
来源期刊：Therapeutic Advances in Medical OncologyDOI：10.1177/1758835919850665
Microwave ablation versus resection for hepatocellular carcinoma within the Milan criteria: a propensity-score analysis
来源期刊：Therapeutic Advances in Medical OncologyDOI：10.1177/1758835919874652
Real-world efficacy and safety of liposomal irinotecan plus fluorouracil/leucovorin in patients with metastatic pancreatic adenocarcinoma: a study by the Korean Cancer Study Group
来源期刊：Therapeutic Advances in Medical OncologyDOI：10.1177/1758835919871126
Cytoreductive nephrectomy in the current treatment algorithm
来源期刊：Therapeutic Advances in Medical OncologyDOI：10.1177/1758835919879026
KRAS and ERBB-family genetic alterations affect response to PD-1 inhibitors in metastatic nonsquamous NSCLC
来源期刊：Therapeutic Advances in Medical OncologyDOI：10.1177/1758835919885540
FAM84B promotes prostate tumorigenesis through a network alteration
来源期刊：Therapeutic Advances in Medical OncologyDOI：10.1177/1758835919846372
Patterns of treatment and outcome with 500-mg fulvestrant in postmenopausal women with hormone receptor-positive/HER2-negative metastatic breast cancer: a real-life multicenter Italian experience
来源期刊：Therapeutic Advances in Medical OncologyDOI：10.1177/1758835919833864
The risk of liver cancer in autoimmune liver diseases
来源期刊：Therapeutic Advances in Medical OncologyDOI：10.1177/1758835919861914
Characteristics and survival of older patients with metastatic pancreatic cancer: a retrospective analysis of the AC Camargo Cancer Center experience
来源期刊：Therapeutic Advances in Medical OncologyDOI：10.1177/1758835919874650
Ratio of carcinoembryonic antigen in pleural fluid and serum for the diagnosis of malignant pleural effusion
来源期刊：Therapeutic Advances in Medical OncologyDOI：10.1177/1758835919850341
High-CLDN4 ESCC cells harbor stem-like properties and indicate for poor concurrent chemoradiation therapy response in esophageal squamous cell carcinoma
来源期刊：Therapeutic Advances in Medical OncologyDOI：10.1177/1758835919875324
Pemetrexed/carboplatin plus gefitinib as a first-line treatment for EGFR-mutant advanced nonsmall cell lung cancer: a Bayesian network meta-analysis
来源期刊：Therapeutic Advances in Medical OncologyDOI：10.1177/1758835919891652
CD8+ PD-1+ T-cells and PD-L1+ circulating tumor cells in chemotherapy-naïve non-small cell lung cancer: towards their clinical relevance?
来源期刊：Therapeutic Advances in Medical OncologyDOI：10.1177/1758835919853193
Neoadjuvant zoledronic acid for HER2-positive breast cancer: the Zo-NAnTax trial
来源期刊：Therapeutic Advances in Medical OncologyDOI：10.1177/1758835919853971
Adjuvant therapy for pancreatic body or tail adenocarcinoma: a study of the National Cancer Database
来源期刊：Therapeutic Advances in Medical OncologyDOI：10.1177/1758835919842438
Do all patients with advanced N-stage nasopharyngeal carcinoma benefit from the addition of induction chemotherapy to concurrent chemoradiotherapy?
来源期刊：Therapeutic Advances in Medical OncologyDOI：10.1177/1758835919833863
Novel multi-drugs incorporating hybrid-structured nanofibers enhance alkylating agent activity in malignant gliomas
来源期刊：Therapeutic Advances in Medical OncologyDOI：10.1177/1758835919875555
Targeting CDK9 and MCL-1 by a new CDK9/p-TEFb inhibitor with and without 5-fluorouracil in esophageal adenocarcinoma
来源期刊：Therapeutic Advances in Medical OncologyDOI：10.1177/1758835919864850
Major innovations and clinical applications of disodium-levofolinate: a review of available preclinical and clinical data
来源期刊：Therapeutic Advances in Medical OncologyDOI：10.1177/1758835919853954
The incidence and relative risk of adverse events in patients treated with bisphosphonate therapy for breast cancer: a systematic review and meta-analysis
来源期刊：Therapeutic Advances in Medical OncologyDOI：10.1177/1758835919855235
An RB-1 loss of function gene signature as a tool to predict response to neoadjuvant chemotherapy plus anti-HER2 agents: a substudy of the NeoALTTO trial (BIG 1-06)
来源期刊：Therapeutic Advances in Medical OncologyDOI：10.1177/1758835919891608
Regorafenib in glioblastoma recurrence: how to deal with conflicting ‘real-life’ experiences?
来源期刊：Therapeutic Advances in Medical OncologyDOI：10.1177/1758835919887667
Corrigendum to Real-world comparative effectiveness of nab-paclitaxel plus gemcitabine versus FOLFIRINOX in advanced pancreatic cancer: a systematic review
来源期刊：Therapeutic Advances in Medical OncologyDOI：10.1177/1758835919871363
The effect of CELLFOODTM on radiotherapy or combined chemoradiotherapy: preclinical evidence
来源期刊：Therapeutic Advances in Medical OncologyDOI：10.1177/1758835919878347
TROP2 overexpression in colorectal liver oligometastases is associated with poor prognosis after liver resection
来源期刊：Therapeutic Advances in Medical OncologyDOI：10.1177/1758835919897543
